Immunome, Inc.
NASDAQ:IMNM
Overview | Financials
Company Name | Immunome, Inc. |
Symbol | IMNM |
Currency | USD |
Price | 15.97 |
Market Cap | 959,068,768 |
Dividend Yield | 0% |
52-week-range | 6.65 - 30.958 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Clay B. Siegall Ph.D. |
Website | https://immunome.com |
An error occurred while fetching data.
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD